Efficacy of omarigliptin, once-weekly dipeptidyl peptidase-4 inhibitor, in patients with type 2 diabetes

BACKGROUND: Omarigliptin is one of several once-weekly dipeptidyl peptidase-4 inhibitors (DPP-4is). Despite the high frequency of switching from various daily DPP-4is to omarigliptin in actual clinical practice, data regarding its efficacy in patients with type 2 diabetes (T2D) after switching are l...

Descripción completa

Detalles Bibliográficos
Autores principales: Kawasaki, Eiji, Nakano, Yuko, Fukuyama, Takahiro, Uchida, Aira, Sagara, Yoko, Tamai, Hidekazu, Tojikubo, Masayuki, Hiromatsu, Yuji, Koga, Nobuhiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2021
Materias:
Retrospective Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8696643/
https://www.ncbi.nlm.nih.gov/pubmed/35047122
http://dx.doi.org/10.4239/wjd.v12.i12.2087

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8696643/
https://www.ncbi.nlm.nih.gov/pubmed/35047122
http://dx.doi.org/10.4239/wjd.v12.i12.2087

Ejemplares similares